EZRI_BOVIN VIL2 ELISA tesk kit
- Known as:
- EZRI_BOVIN VIL2 Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen16681
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- EZRI_BOVIN VIL2 ELISA tesk kit
Related genes to: EZRI_BOVIN VIL2 ELISA tesk kit
- Gene:
- EZR NIH gene
- Name:
- ezrin
- Previous symbol:
- VIL2
- Synonyms:
- -
- Chromosome:
- 6q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2015-09-11
Related products to: EZRI_BOVIN VIL2 ELISA tesk kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: EZRI_BOVIN VIL2 ELISA tesk kit
- Type 2 diabetes mellitus (T2DM) is among the most rapidly increasing metabolic disorders worldwide. Membrane proteins, integral components of biological membranes, are pivotal in insulin signal transduction and significantly contribute to the pathogenesis of T2DM. However, the systematic investigation of membrane proteins linked to T2DM remains insufficient. - Source: PubMed
Publication date: 2026/07/24
Liu TongTang ZhaoyuanAierken ZulipikaerZhang JieLei Cheng - Atopic Dermatitis (AD) is a chronic inflammatory skin disease characterized by complex pathogenesis, variable clinical phenotypes, and broad severity spectrum. We utilized a serum-proteomic approach integrated with machine learning (ML) to identify novel biomarkers that distinguish mild from severe AD. - Source: PubMed
Publication date: 2026/07/31
Lally Jag SYoshida TakeshiGao ShanCai XueyaLeung Donald Y MBeck Lisa ADe Benedetto Anna - Prostate cancer (PCa) exhibits highly heterogeneous clinical outcomes, underscoring the need for biomarkers that more closely reflect tumor biology. While programmed cell death (PCD) is fundamental to tumor suppression, the prognostic impact of individual PCD pathways remains poorly characterized in PCa. - Source: PubMed
Publication date: 2026/07/22
Luo XingHuang ZeyuDeng MinLiu JinguiLiao ChaoyuYang YouhaoMeng ZhaoyuYuan JianxuXu JiahaoLiu YuxuanWang QiulinWang ZhihaoLi HaoShi RonghuiZeng HanSu ShuaiLiu LiangZheng Ji - Cervical cancer (CC) ranks among the most prevalent malignant neoplasms affecting women worldwide. Tumor recurrence, distant metastases, and chemotherapy resistance significantly hinder long-term clinical survival and therapeutic outcomes. Clinical studies indicate a heightened prevalence of depressive symptoms and major depressive disorder (MDD) among CC patients, suggesting the possibility of bidirectional adverse biological interactions between cervical tumor progression and depressive states. However, the shared molecular signatures underlying both cervical carcinoma and depressive disorders have yet to be fully elucidated, highlighting the need for identifying reliable molecular markers for supplementary diagnosis and prognostic stratification of CC. - Source: PubMed
Publication date: 2026/07/20
Zhang Hua-HuaLiu MinChen Ya-NiZhang Ming-RuZhang JingHe Jing - Introduction Adult attention-deficit/hyperactivity disorder (ADHD) is a clinically important neurodevelopmental condition with a substantial global prevalence. Extended-release guanfacine (GXR) is a non-stimulant selective α2A-adrenergic receptor agonist approved for adult ADHD in Japan, but real-world adult data remain limited. Materials and methods We conducted a retrospective medical chart review of consecutive eligible adults with ADHD treated with GXR at an ADHD specialty clinic in Japan. ADHD was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria by experienced psychiatrists. Clinical Global Impression-Severity (CGI-S), GXR dose, treatment continuation at week 10, Clinical Global Impression-Improvement (CGI-I), and treatment-emergent adverse events (TEAEs) were extracted from medical records. Continuous variables were summarized as mean±standard deviation (SD) and categorical variables as number and percentage. Exact binomial 95% confidence intervals (CIs) were calculated for proportions. Exploratory baseline comparisons by treatment continuation status were performed using the Shapiro-Wilk test, Welch t-test, or Mann-Whitney U test for continuous variables and the Fisher exact test for categorical variables. Statistical analyses were performed using EZR, a graphical user interface for R. Results Among 137 participants, 111 (81%; 95% CI: 73.4-87.2%) continued GXR treatment for 10 weeks. Among the 111 participants with week-10 CGI-I data, 58 (52.3%; 95% CI: 42.6-61.8%) were rated as very much improved or much improved. TEAEs were recorded in 76 participants (55.5%; 95% CI: 46.7-64%), and no serious TEAEs were observed. Conclusions These findings suggest that GXR may be a clinically useful and generally well-tolerated treatment option for adults with ADHD in routine practice in Japan. The results support cautious real-world titration and highlight the need for prospective studies using standardized adult ADHD outcome measures. - Source: PubMed
Publication date: 2026/06/01
Suzuki HirohisaHayashi WakahoNakamura DanSeki ShizukaHanawa YouichiYamauchi MisatoNakamura YoshifumiSugita ShutaroSanada KenjiIwanami Akira